Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Research & Development (2019 - 2026)

InMed Pharmaceuticals has reported Research & Development over the past 5 years, most recently at $630636.0 for Q4 2025.

  • For Q4 2025, Research & Development fell 29.55% year-over-year to $630636.0; the TTM value through Dec 2025 reached $2.2 million, down 23.23%, while the annual FY2025 figure was $2.9 million, 11.3% down from the prior year.
  • Research & Development for Q4 2025 was $630636.0 at InMed Pharmaceuticals, up from $581612.0 in the prior quarter.
  • Over five years, Research & Development peaked at $2.5 million in Q4 2021 and troughed at $112720.0 in Q2 2025.
  • A 5-year average of $1.0 million and a median of $864829.5 in 2022 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: surged 46.8% in 2024 and later crashed 82.89% in 2025.
  • Year by year, Research & Development stood at $2.5 million in 2021, then crashed by 66.44% to $851356.0 in 2022, then fell by 28.37% to $609791.0 in 2023, then surged by 46.8% to $895176.0 in 2024, then decreased by 29.55% to $630636.0 in 2025.
  • Business Quant data shows Research & Development for INM at $630636.0 in Q4 2025, $581612.0 in Q3 2025, and $112720.0 in Q2 2025.